Investigators found PIK3CA mutations highly associated with late-stage metastatic cells while being extremely rare in early disseminated cancer cells (DCCs). [Nature Communications]
Scientists investigated the role of deubiquitinases (DUB) in regulating estrogen receptor α (ERα) in breast cancer. An RNAi loss-of-function screen in breast cancer cells targeting all DUB identified USP11 was a regulator of ERα transcriptional activity, which was further validated by assessment of direct transcriptional targets of ERα. [Cancer Research]
The loss of SNAI2 in cancer-associated fibroblasts limited the production of some cytokines, which influenced AKT/ERK tumor signaling and subsequent proliferative and metastatic capacity of ERBB2+ breast cancer cells. [Cancer Research]
The authors revealed reciprocal regulation of early growth response 1 (EGR1) and EZH2: EGR1 activated the expression of EZH2, and EZH2 represses EGR1 expression. [Oncogene]
Investigators used inducible genetic depletion and two distinct pharmacological inhibitors to investigate the therapeutic potential of targeting SH2 containing protein tyrosine phosphatase-2 (SHP2) in metastatic breast cancer. [Oncogene]
Researchers isolated macrophages from mice and humans, polarized them ex vivo, and examined their functional interaction with breast cancer cells in culture and in mice. [Science Signaling]
The authors employed laser microdissection and whole-transcriptome profiling of the breast epithelium prior to and post tumor diagnosis to identify the earliest alterations in breast carcinogenesis. [npj Breast Cancer]
The expression of lysine demethylase 2A in cancer-associated fibroblasts was studied using immunohistochemical staining and its association with clinicopathological features and patient’s survival was tested. [British Journal of Cancer]
The effect of SLC38A2 knockdown in glutamine-sensitive cell lines was analyzed. The prognostic value of SLC38A2 in a cohort of breast cancer was determined by immunohistochemistry. [British Journal of Cancer]
Scientists recognized the tumor suppressor gene Phosphatase and Tensin homolog (PTEN) as a potential gene causing chromosomal instability in TNBC and showed that TNBC with low expression levels of PTEN could be sensitized for the treatment with poly-(ADP-ribose)-polymerase 1 (PARP1) inhibitors, independent of Breast Cancer (BRCA) mutations or a BRCA-like phenotype. [Cancers]
Investigators showed that, in addition to PI3K, WAVE3 tyrosine phosphorylation could also be achieved downstream of TGF-β and EGF and that WAVE3 tyrosine phosphorylation was required for its oncogenic activity. [Oncogenesis]
RNA sequencing of IBC samples from The Cancer Genome Atlas was acquired. Alternative splicingevents were screened by conducting univariate and multivariate Cox analysis and least absolute shrinkage and selection operator regression. [Scientific Reports]
Microgravity (µg) research might be an unusual method to combat the disease, but cancer biologists decided to harness the power of µg as an exceptional method to increase efficacy and precision of future breast cancer therapies. [International Journal of Molecular Sciences]
The authors presents the phenotype characteristics of EO771 and its sensitivity to nutrients and different therapies such as radiotherapy, chemotherapy, hormone therapy, and immunotherapy. [Cancer Medicine]
Agendia Inc. announced the availability of local testing for its CE-marked MammaPrint® BluePrint® Breast Cancer Recurrence and Molecular Subtyping tests, provided by PathoNext lab in Leipzig, Germany. Breast cancer patients in Germany will now have access to state-of-the art genomic profiling in their own country. [Agendia Inc.]
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
